acenocoumarol / Generic mfg. - LARVOL DELTA

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS (clinicaltrials.gov) - P=N/A | N=150 | Recruiting | Sponsor: McMaster University | Trial completion date: Dec 2027 ➔ Dec 2029 | Trial primary completion date: Jul 2027 ➔ Jul 2029

Trial completion date • Trial primary completion date • Cardiovascular • Genetic Disorders • Hematological Disorders • Thrombosis

Point-of-Care Agitated Saline Contrast Echocardiography in the Diagnosis of Respiratory Failure: A Case of Hepatopulmonary Syndrome With Decompensated Heart Failure. (PubMed, Cureus) - "Past medical history was notable for dilated alcoholic cardiomyopathy, heart failure with reduced ejection fraction (New York Heart Association (NYHA) class II, left ventricle ejection fraction (LVEF) 30%), permanent atrial fibrillation (AF) (on bisoprolol and anticoagulation with acenocoumarol), and a prior mitral valve prosthesis...However, despite high-flow nasal oxygen therapy, subsequent noninvasive ventilation(NIV) (fraction of inspired oxygen (FiO₂) 1.0), and pharmacologic therapy with furosemide resulting in satisfactory diuresis (250 mL/h) and reduced pulmonary congestion on lung ultrasound, oxygenation improved only minimally (PaO₂ up to 40 mmHg), and dyspnea persisted.  Given the presence of cirrhosis with portal hypertension and refractory hypoxemia, and that a workup for HPS had not yet been performed, a bedside agitated-saline contrast echocardiography was performed at the point of care. Microbubbles appeared in the left atrium (LA) and..."

Journal • Addiction (Opioid and Alcohol) • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Gastroenterology • Heart Failure • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Transplantation

Fetal posterior cerebral artery infarction due to carotid dissection: a case report. (PubMed, J Med Case Rep) - "Fetal posterior cerebral artery and internal carotid artery dissection are frequent separately, but their co-occurrence is exceptional. This report broadens the spectrum of internal carotid artery dissection and discusses the role of fetal posterior cerebral artery in ischemic stroke pathogenesis."

Journal • Cardiovascular • CNS Disorders • Hypertension • Ischemic stroke • Mood Disorders

Time for a Paradigm Shift in Vitamin K Antagonist Reversal - Embracing TGA over INR for Optimal Outcomes? (ASH 2023) - "Participants were pre-treated for 10 days with acenocoumarol to achieve an INR between 2 and 3 (± 10% inclusive)... After 4F-PCC infusion, clotting factors II, VII, IX and X showed dose-dependent increases at 30 min post-dose. Correspondingly, a dose-dependent TGA response was observed; 4F-PCC resulted in restoration to levels measured before anticoagulation with VKA. The degree of INR normalization appeared to be slightly more pronounced in the higher dosed 4F-PCC group."

Thrombosis

Apixaban Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with End-Stage Kidney Disease on Hemodialysis and with Atrial Fibrillation (ASH 2023) - "Patients in the VKA group received Acenocoumarol. There were no significant differences regarding in all-cause mortality, 18.8% versus 21.5% respectively. CONCLUSIONS Compared to VKA, our findings suggest that low dose of apixaban is a safe and effective alternative in patients with AF and ESKD on hemodialysisis and low dose of apixaban showed predictable pharmacokinetic."

Clinical • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Ischemic stroke • Myocardial Infarction • Nephrology • Renal Disease

Safety of contraception among women using anticoagulant therapy: an updated systematic review. (PubMed, Contraception) - "Women on anticoagulant therapy are at risk for recurrent thrombosis and bleeding, which might be further exacerbated with use of certain contraceptive methods. Additional evidence is needed on safety of concurrent use of anticoagulant medications and contraceptives."

Journal • Review • Cardiovascular • Hematological Disorders • Long-acting Reversible Contraceptives • Venous Thromboembolism

RISK OF ISCHAEMIC STROKE AND INTRACRANIAL BLEEDING WITH DIRECT-ACTING ORAL ANTICOAGULANTS AND WARFARIN COMPARED TO ACENOCOUMAROL (WSC 2025) - "Background and Aims: Most clinical trials and observational studies conducted with direct-acting oral anticoagulants (DOAC: dabigatran, rivaroxaban, apixaban and edoxaban) have used warfarin as the comparator drug. The results suggest that conclusions drawn from studies using warfarin as the reference drug should not be automatically extrapolated to acenocoumarol."

Atrial Fibrillation • Cardiovascular • Ischemic stroke

Monitoring and Follow-Up of Patients on Vitamin K Antagonist Oral Anticoagulant Therapy Using Artificial Intelligence: The AIto-Control Project. (PubMed, J Clin Med) - "Background: Vitamin K antagonist oral anticoagulant (VKA) therapy, using warfarin or acenocoumarol in our health system, is indicated, according to clinical guidelines, for the prophylaxis of thromboembolic events. Additionally, it aims to ease the workload on both primary care and hospital services. These outcomes will be achieved through the involvement of advanced practice nurses who will supervise app-based monitoring and patient education."

Journal • Cardiovascular

Personalized management of acenocoumarol dosage using eGFR: Analysis of INR data in a cohort of 204 patients. (PubMed, Int J Clin Pharmacol Ther) - "Renal function, as measured by BSA-adjusted eGFR, is a critical determinant of acenocoumarol dose requirements. These findings support the inclusion of renal function in future acenocoumarol dose calculators and emphasize the importance of individualized dosing strategies."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Insights into the alteration of vaginal microbiota and metabolites in pregnant woman with preterm delivery: prospective cohort study. (PubMed, Front Cell Infect Microbiol) - "In addition, vaginal metabolomics-based LC-Orbitrap-MS/MS revealed that the contents of 2-Piperidone, Melphalan, N-acetylputrescine, Obatoclax, Eurostoside, Pregnanediol 3-O-glucuronide, O-Phospho-L-serine, 1-Kestose and N-arachidonylglycine were significantly decreased in the PrPG group compared with the PrTG group, while Acenocoumarol, Isopyrazam, Pentosidine, hexose, 7-Hydroxymitragynine, PE, Tamoxifen and 1-Deoxynojirimycin contents were significantly increased. These results suggest that specific bacterial species and metabolites may serve as potential biomarkers for preterm birth prediction, and approve the theoretical basis for the intervention of preterm birth."

Journal

Tyrosine Kinase Inhibitor Treatment of a Patient with Chronic Myeloid Leukemia and Congenital Thrombophilia. (PubMed, Hematol Rep) - "Case Presentation: A 33-year-old woman with congenital thrombophilia (type I protein S deficiency and heterozygous Factor V Leiden mutation) and a history of VTE on long-term anticoagulation with acenocoumarol presented with CML. She exhibited primary resistance to first-line imatinib and poor tolerance with suboptimal response to second-line bosutinib... This case highlights the importance of individualized, multidisciplinary management in CML patients with coexisting thrombophilia. Asciminib, with its favorable cardiovascular safety profile, represents a promising therapeutic option in high-risk patients where other TKIs may be contraindicated due to resistance, intolerance, or thrombotic risk."

Journal • Cardiovascular • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Venous Thromboembolism • PROS1

Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System. (PubMed, J Clin Med) - "Anticoagulants analyzed included warfarin, rivaroxaban, dabigatran, apixaban, edoxaban, betrixaban, and acenocoumarol; antiplatelets included aspirin, clopidogrel, ticagrelor, cilostazol, prasugrel, and dipyridamole. While our findings highlight potential safety signals related to hemorrhage with antithrombotic drug combinations, they remain hypothesis-generating and should not be interpreted as causal associations. Instead, they provide an initial basis for further validation in well-designed clinical cohorts where comorbidities can be adequately accounted for."

Adverse events • Journal • Hematological Disorders

Thrombocheck: a drug-drug interactions guide for cardiologists prescribing antithrombotic therapy (ESC-WCC 2025) - " First, a clinical pharmacist and a physician independently analysed the literature on DDI for 8 AT: 5 OAC (rivaroxaban, apixaban, edoxaban, dabigatran and acenocoumarol) and 3 AA (clopidogrel, ticagrelor and prasugrel). Aspirin was excluded as it is not known for PK DDI... Antithrombotic therapies are susceptible to numerous DDI. This simple yet important tool can help cardiologists minimize significant DDI when prescribing new AT, guiding them toward safer et more effective treatment options."

Cardiovascular

The key determinants of oral anticoagulant treatment experience in atrial fibrillation patients (ESC-WCC 2025) - "NOACs were used by 53% of patients, mainly rivaroxaban (38%), apixaban (11%), and edoxaban (4%), while 47% used VKAs, primarily warfarin (25%) and acenocoumarol (22%). The study highlights that socioeconomic factors, particularly education level and household income, play a crucial role in the perceived convenience and satisfaction with OAC therapy in AF patients. Patients receiving VKA therapy reported lower treatment convenience, possibly due to the need for frequent monitoring and dietary restrictions.These findings underscore the importance of individualized patient support and education to optimize adherence and overall treatment experience in anticoagulated AF patients."

Clinical • Atrial Fibrillation • Cardiovascular • Dyslipidemia

ARGONAUT: Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (clinicaltrials.gov) - P3 | N=340 | Active, not recruiting | Sponsor: Centre Hospitalier Universitaire de Nīmes | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2025 ➔ Feb 2026

Enrollment closed • Trial completion date • Cardiovascular • Heart Failure • Thrombosis

Comparative clinical outcomes of acenocoumarol versus direct oral anticoagulants (DOACs) and warfarin in patients with atrial fibrillation: real-world-evidence (SIESTA-A study). (PubMed, Front Pharmacol) - "The aim of this study was to evaluate the effectiveness and safety of direct oral anticoagulants (DOACs: dabigatran, rivaroxaban, apixaban and edoxaban) and warfarin versus acenocoumarol in patients with atrial fibrillation under real-world clinical practice conditions. Although DOACs were clearly associated with a lower risk of intracranial bleeding compared to acenocoumarol, our data did not reveal a significant reduction in thromboembolic events. Warfarin was found to be both less effective and less safe than acenocoumarol."

Clinical data • HEOR • Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular • Gastroenterology • Ischemic stroke • Pulmonary Embolism • Respiratory Diseases

Acute Coronary Syndrome in a Young Woman With Protein S Deficiency and Von Willebrand Disease Type 1: A Case of Mixed Hemostatic Disorders. (PubMed, Cureus) - "She underwent percutaneous intervention with multiple stents and commenced anticoagulation therapy with acenocoumarol following the identification of partial protein S deficiency (56%)...The anticoagulant regimen was switched to dabigatran...The patient achieved a favorable clinical outcome, characterized by symptom resolution, an absence of new thrombotic or bleeding events, and partial biochemical recovery. This case highlights the importance of comprehensive hematological investigations in young patients presenting with atypical arterial thrombotic events."

Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Hematological Disorders • Hemophilia • Myocardial Infarction • Thrombosis • PROS1

Optimization of vitamin K antagonist treatment: Near patient monitoring versus standard of care a parallel group clinical trial in older patients with atrial fibrillation. (PubMed, Eur J Clin Pharmacol) - "NPTM of VKA treatment in AF-patients does not result in an improved TTR when compared to SOC. All-cause death, total number of minor bleedings and all non-major bleedings may be reduced in NPTM, although the study was not powered for these secondary outcomes. Future studies are needed to determine the cost-effectiveness of NTPM versus SOC."

Journal • Atrial Fibrillation • Cardiovascular • Geriatric Disorders

A comparison of antiplatelet and oral anticoagulation strategies to prevent cerebral microembolism after transcatheter aortic valve implantation: the AUREA trial. (PubMed, EuroIntervention) - "In patients without an indication for OAC, an OAC strategy for 3 months post-TAVI did not show any benefit over an antiplatelet strategy in preventing cerebral microembolism. Patients treated with DAPT showed a lower mean volume of brain damage on DW-MRI during the 90 days following TAVI compared to those treated with acenocoumarol."

Clinical • Journal • Cardiovascular • CNS Disorders • Vascular Neurology

Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile. (PubMed, Cost Eff Resour Alloc) - "Dabigatran is cost-effective and dominates both rivaroxaban and apixaban at current publicly available prices in Chile. In addition, we expect dabigatran-idarucizumab is also expected to be cost-effective for Chilean health system when is compared against acenocoumarol-PCC as reversal agents."

HEOR • Journal • Atrial Fibrillation • Cardiovascular • Hematological Disorders

Long-Term Outcomes of Valve Replacement With Mechanical Prosthesis in Patients With Valvular Heart Disease: A Single-Center Retrospective Study. (PubMed, Cureus) - "Objective To assess the survival outcomes, postoperative complications, and reoperation rates in patients who underwent prosthetic mechanical valve replacement with acenocoumarol and low-dose aspirin (75 mg), with adequate International Normalized Ratio (INR) monitoring. However, early postoperative risks, especially in women and those with advanced heart failure, highlight the need for individualized care and close monitoring. Future research should aim to refine patient selection, explore sex-based outcome disparities, and optimize anticoagulation strategies to further improve survival and quality of life in this population."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

GLANZMANN THROMBASTHENIA AND VENOUS THROMBOSIS : ABOUT 2 CASES (EHA 2025) - "In January 2023, he was admitted for the third episode of melena associated with severe anemia (hemoglobin drop to 5 g/dl) resistant to platelet and red cell transfusions, and continuous infusion of Esomeprazole. This situation necessitated four injections of Novoseven at a dose of 6 mg twice daily for four days, which successfully stopped the bleeding...In 2007, thrombophlebitis of the right lower limb was discovered, and treated with anti-vitamin K (Sintrom*), which was stopped after five months due to recurrent hemorrhagic syndrome and thrombosis permeability... Those observations showed that a severe thrombotic process may occur even in GT.The occurrence of venous thrombosis in our cases is due to the injection of recombinant factor VIIa and the central catheter in one case, and estrogen-progestogen therapy in the second case. The use of unfractionated heparin and low-molecular-weight heparin in the 1st case remains the treatment of choice while the role of new oral..."

Clinical • Anemia • Cardiovascular • Gastroenterology • Hematological Disorders • Pain • Pulmonary Embolism • Respiratory Diseases • Thrombosis

IDENTIFICATION OF NEW MOLECULAR MECHANISMS OF ANTITHROMBIN DEFICIENCY: RESULTS FROM A POLISH COHORT (EHA 2025) - "Thirteen probands (54.2%) received DOAC: six (25.1%) rivaroxaban (20 mg qd), five (20.8%) apixaban (2.5 mg or 5 mg bid) and two (8.3%) dabigatran (150 mg bid). Six probands were under anti-vitamin K treatments: four (16.7%) warfarin (8 or 10 mg qd) and two (8.3%) acenocoumarol (4 mg qd). Finally, four (16.7%) patients received antiplatelet therapy with acetylsalicylic acid (75 mg qd) and one (4.1%) received enoxaparin (150 mg/kg body weight qd).NGS detected SERPINC1 variants in 25 cases (86.2%): 12 missense (48%), 1 new (c.457T>C); 6 small deletions/insertions (24%), 2 new (c.962insG; c.402_403delGA+c.406_408+delGAGG), 5 intronic (20%) and 2 nonsense (8%)... Our study highlights the wide genetic heterogeneity involved in AT deficiency. We identified new genetic defects in SERPINC1, including intronic variants and confirmed the role of retrotransposon insertions as a new under-recognized mechanism contributing to congenital AT deficiency through in the genetic..."

Cardiovascular • Hematological Disorders • Respiratory Diseases • Venous Thromboembolism

Comparison of INR Values Obtained Using a Traditional Method and a Point-of-Care Device (ISTH 2025) - "Methods A total of 182 INR measurements from patients on vitamin K antagonists (acenocoumarol and warfarin) were grouped into three ranges: 1–1.99 (n=82), 2–3.5, (n=79) and >3.5 (n=21). Results The results are summarized in the Table 1 and Table 2High agreement was observed within the therapeutic range (2–3.5), while variability increased at INR levels >3.5, consistent with the sensitivity of thromboplastins to reduced vitamin K-dependent factors such as Factor VII. Table or Figure Upload"

A PHASE IB, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED MOSUNETUZUMAB IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2025) - P1 | "Four of 15 patients experienced a total of 5 cytokine release syndrome (CRS) events; all were Grade 1-2 and none required tocilizumab administration...One patient receiving concomitant acenocoumarol experienced a transient increase in international normalised ratio due to expected cytochrome P450 inhibition by transient cytokine release, requiring acenocoumarol dose adjustment... Preliminary data from this Phase Ib study indicated that mosunetuzumab exhibits an acceptable safety profile in patients with SLE and that its PK profile in the SLE population is closely aligned with that observed in the relapsed or refractory NHL population. Deep B-cell depletion in the higher-dose cohorts demonstrated the potential for treating B-cell–driven autoimmune diseases. Whilst this study was designed to evaluate the safety and PK profile of mosunetuzumab with a limited dosing regimen, there did appear to be a positive impact on clinical activity."

Clinical • PK/PD data • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lupus • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Systemic Lupus Erythematosus • CD4 • CD8